{"id":175287,"date":"2019-09-01T18:34:45","date_gmt":"2019-09-01T18:34:45","guid":{"rendered":"https:\/\/bm.dev.synology.me\/?p=175287"},"modified":"2019-09-01T18:34:45","modified_gmt":"2019-09-01T18:34:45","slug":"financial-times-companiile-biotehnologice-combat-teama-de-o-apocalipsa-a-antibioticelor","status":"publish","type":"post","link":"https:\/\/bm.dev.synology.me\/?p=175287","title":{"rendered":"Financial Times: Companiile biotehnologice combat teama de \u201eo apocalips\u0103 a antibioticelor\u201d"},"content":{"rendered":"<p>\nJurnali\u015ftii din domeniul \u015ftiin\u0163ei primesc \u00een general dou\u0103 p\u0103reri contradictorii \u00een ceea ce prive\u015fte cre\u015fterea pericolului generat de rezisten\u0163a microbilor la antibiotice.<\/p>\n<p>\nPe de-o parte, exist\u0103 avertismente privind un viitor dezastru al antibioticelor, av\u00e2nd \u00een vedere c\u0103 germenii \u015fi microbii dezvolt\u0103 o rezisten\u0163\u0103 la medicamentele actuale, \u00een timp ce problemele economice \u00eempiedic\u0103 dezvoltarea unor antibiotice noi.<\/p>\n<p>\nPe de alt\u0103 parte, studiile publicate de universit\u0103\u0163i \u015fi companii din domeniul biotehnologiei din lume descriu progrese semnificative \u00een cercetare.<\/p>\n<p>\n\u00cens\u0103, aceste dou\u0103 impresii contradictorii nu sunt, de fapt, contradictorii. R\u0103sp\u00e2ndirea super-bacteriilor rezistente la majoritatea medicamentelor determin\u0103 activitatea de cercetare, sus\u0163inut\u0103 de guverne, institu\u0163ii caritabile \u015fi financiare.<\/p>\n<p>\nFondatorul principal este Carb-X, o organiza\u0163ie non-profit global\u0103 a Universit\u0103\u0163ii din Boston. ONG-ul a investit peste 500 de milioane de dolari \u00een perioada 2016-2021, pentru a avansa anumite proiecte \u00een fazele incipiente ale studiilor clinice. Portofoliul Carb-X cuprinde 29 de proiecte din cnci \u0163\u0103ri, cu scopul de \u201ea accelera dezvoltare a medicamentelor pentru a combate super-microbii\u201d, conform lui Kevin Outterson, directorul executiv a Carb-X.<\/p>\n<p>\nProblema este c\u0103 industria farmaceutic\u0103 beneficiaz\u0103 de pu\u0163ine stimulente financiare pentru a transpune proiectele \u00een etapa studiilor clinice, care devin mult prea costisitoare pentru companiile mici.<\/p>\n<p>\nAcest e\u015fec al pie\u0163ei are mai multe cauze, printre care pre\u0163ul foarte mic al antibioticelor existente, faptul c\u0103 acestea sunt luate doar pentru o perioad\u0103 scurt\u0103 de timp \u015fi p\u0103strarea antibioticelor eficiente doar pentru cazuri extreme, din cauza fricii de supradoz\u0103.<\/p>\n<p>\n<a href=\"https:\/\/www.mediafax.ro\/externe\/financial-times-companiile-biotehnologice-combat-teama-de-o-apocalipsa-a-antibioticelor-18344709\/foto\">Cititi mai multe pe www.mediafax.ro<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Companiile din domeniul biotehnologiei doresc s\u0103 combat\u0103 teama de \u201eo apocalips\u0103 a antibioticelor\u201d, \u00een contextul \u00een care pia\u0163a ofer\u0103 pu\u0163ine impulsuri pentru dezvoltarea unor noi antibiotice, iar rezisten\u0163a microbilor la antibiotice este \u00een cre\u015ftere, relateaz\u0103 publica\u0163ia Financial Times.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[510],"tags":[7658,15785,18526,201],"class_list":["post-175287","post","type-post","status-publish","format-standard","hentry","category-actualitate","tag-antibiotice","tag-apocalipsa","tag-combatere","tag-companii"],"_links":{"self":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts\/175287","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=175287"}],"version-history":[{"count":0,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=\/wp\/v2\/posts\/175287\/revisions"}],"wp:attachment":[{"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=175287"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=175287"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bm.dev.synology.me\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=175287"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}